Cardiology

Researchers from Mayo Clinic and the Johns Hopkins University School of Medicine published an article in “JAMA Internal Medicine” outlining the elimination from clinical practice of a popular test for diagnosing heart attacks.

By Kelley Schreiber • August 15, 2017

Sudden cardiac death and episodes of fainting and seizures from long QT syndrome are significantly lower than previously thought when patients are diagnosed and treated at a specialty center dedicated to the treatment of genetic heart rhythm diseases, according to Mayo Clinic research published in the Journal of the American College of Cardiology.

By Mayo Clinic News Network • July 20, 2017

Clinical Laboratory News recently highlighted a Mayo Clinic study that shows how plasma ceramides may predict cardiovascular events in patients with or without coronary artery disease.

By Kelley Schreiber • May 12, 2017

European Heart Journal recently highlighted Mayo Clinic’s new blood test that may predict cardiovascular events in patients with or without coronary artery disease.

By Kelley Schreiber • May 5, 2017

Cardiovascular specimens are commonly encountered in clinical practice, but there is a lack of formal (uniform) specimen handling, training, and reporting. These modules will address the value and limitations of new ancillary diagnostic techniques that are relevant and actionable for clinicians.

By MML Education • March 28, 2017

Jeff Meeusen, Ph.D., a clinical chemist and Co-Director of Cardiovascular Laboratory Medicine at Mayo Clinic, discussed Mayo Clinic’s new blood test that helps combat the leading cause of death in the U.S. on Voice of America.

By Kelley Schreiber • March 22, 2017

Jeff Meeusen, Ph.D., a clinical chemist and Co-Director of Cardiovascular Laboratory Medicine at Mayo Clinic, discussed Mayo Clinic’s new blood test that helps combat the leading cause of death in the U.S. with KTTC. Read this post to view the story.

By Kelley Schreiber • March 16, 2017

A new type of blood test may help physicians identify which patients with and without evidence of coronary blockages are at risk for heart attacks and strokes. Even individuals with normal levels of low-density lipoprotein (LDL), known as the so-called “bad” cholesterol, but still at risk, seem to be identified.

By Mayo Clinic News Network • March 14, 2017

This week’s Research Roundup highlights the clinical and pathological evolution of giant cell arteritis with a prospective study of follow-up temporal artery biopsies in 40 treated patients.

By Kelley Schreiber • March 13, 2017

This week’s Research Roundup highlights outcomes of warfarin therapy for bioprosthetic valve thrombosis of surgically implanted valves.

By Kelley Schreiber • March 6, 2017

ST2 is a biomarker of fibrosis and cardiac remodeling and provides clinicians with significant prognostic guidance without being adversely influenced by typical confounders such as age, obesity, and renal impairment.

By Alyssa Frank • October 26, 2016

Mayo Clinic has launched a new type of blood test that will be used to predict adverse cardiovascular events in patients with progressing coronary artery disease. The test measures blood concentrations of plasma ceramides, a class of lipids that are highly linked to cardiovascular disease processes.

By Kelley Schreiber • August 10, 2016

Mayo Medical Laboratories has launched a new type of blood test that will be used to predict adverse cardiovascular events in patients with progressing coronary artery disease. A recent article in Clinical Lab Products takes a closer look at the test.

By Kelley Schreiber • August 4, 2016